TREATMENT AND OUTCOMES OF ELDERLY OVARIAN CANCER PATIENTS: A POPULATION-BASED ANALYSIS

2016 ◽  
Author(s):  
Melinda Schuurman
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Population Based

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

1998 ◽  
Vol 16 (2) ◽  
pp. 397-404 ◽  
Author(s):  
O T Jóhannsson ◽  
J Ranstam ◽  
A Borg ◽  
H Olsson
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Matched Control ◽  
Brca1 Mutation ◽  
Population Based ◽  
Control Group ◽  
Breast And Ovarian Cancer ◽  
Population Based Study ◽  
Matched Control Group ◽  
Group Survival

PURPOSE Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated. PATIENTS AND METHODS The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group. RESULTS No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1-associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8). CONCLUSION The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.

End-of-life care for Medicare beneficiaries with ovarian cancer: Evaluation of intensity and rate of hospitalizations.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9523-9523
Author(s):  
Alexi A. Wright ◽  
Craig Earle ◽  
Nancy Lynn Keating
Keyword(s):  
Ovarian Cancer ◽  
Medical Care ◽  
End Of Life ◽  
Cancer Patients ◽  
High Intensity ◽  
Population Based ◽  
Medicare Beneficiaries ◽  
National Cohort ◽  
Ed Visits ◽  
Over Time

9523 Background: Patients with advanced cancer are receiving increasingly aggressive medical care at the end-of-life (EOL). Population-based studies have not examined the medical care that ovarian cancer patients receive near death. Methods: We identified a national cohort of 6,956 Medicare beneficiaries who were living in Surveillance, Epidemiology, and End Results (SEER) areas, were diagnosed with epithelial ovarian cancer between 1996 and 2007, and died from ovarian cancer by December 2007. Using multivariable models, we examined rates of aggressive medical care within 30 days of death over time and examined indications for hospitalizations near death. Results: Adjusted rates of intensive care unit (ICU) admissions and emergency department (ED) visits increased significantly between 1996 and 2007 (ICU: 6.4% to 16.6%, p<0.0001 and ≥2 ED visits: 19.7% to 32.1%, p<0.0001). In contrast, late (within 7 days death) or absent hospice referrals decreased (63.1% to 47.8%, p<0.001) and chemotherapy use within 30 days of death decreased slightly (8.1% vs. 7.1%; p=0.04). Although terminal hospitalizations decreased (28.0% to 19.1%, p=0.001), rates of hospitalizations near death increased over time (41.4% vs. 45.3%, p=0.01). The most common indications for hospitalization included: bowel obstructions (20.0%), infections (10.4%), fluid or electrolyte abnormalities (9.2%), and malignant effusions (8.1%). Conclusions: Despite significant increases in the use of hospice near death, utilization of ICUs, EDs, and acute inpatient care at the EOL rose significantly between 1997 and 2007 for older ovarian cancer patients. Future studies should examine whether this high-intensity health care is avoidable given evidence that high-intensity care is associated with lower patient quality-of-life near death and increased complications in bereaved caregivers.

scholarly journals Adequacy of family history taking in ovarian cancer patients: a population-based study

2012 ◽  
Vol 11 (3) ◽  
pp. 343-349 ◽  
Author(s):  
Anne M. van Altena ◽  
Sandra van Aarle ◽  
Lambertus A. L. M. Kiemeney ◽  
Nicoline Hoogerbrugge ◽  
Leon F. A. G. Massuger ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Family History ◽  
Cancer Patients ◽  
Population Based ◽  
History Taking ◽  
Population Based Study

scholarly journals Statin use and mortality among ovarian cancer patients: A population-based cohort study

2017 ◽  
Vol 141 (2) ◽  
pp. 279-286 ◽  
Author(s):  
Freija Verdoodt ◽  
Merete Kjaer Hansen ◽  
Susanne K. Kjaer ◽  
Anton Pottegård ◽  
Søren Friis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Cancer Patients ◽  
Population Based ◽  
Statin Use

scholarly journals Bowel obstruction in elderly ovarian cancer patients: A population-based study

2013 ◽  
Vol 129 (1) ◽  
pp. 107-112 ◽  
Author(s):  
Stephen J. Mooney ◽  
Megan Winner ◽  
Dawn L. Hershman ◽  
Jason D. Wright ◽  
Daniel L. Feingold ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Bowel Obstruction ◽  
Population Based ◽  
Population Based Study

scholarly journals A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Gillian E. Hanley ◽  
Jessica N. McAlpine ◽  
Dianne Miller ◽  
David Huntsman ◽  
Kasmintan A. Schrader ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Prevention ◽  
Cancer Patients ◽  
Population Based ◽  
Brca1 And Brca2 ◽  
Brca1 And Brca2 Testing

scholarly journals Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients

2019 ◽  
Vol 37 (15) ◽  
pp. 1305-1315 ◽  
Author(s):  
Allison W. Kurian ◽  
Kevin C. Ward ◽  
Nadia Howlader ◽  
Dennis Deapen ◽  
Ann S. Hamilton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Genetic Testing ◽  
Cancer Patients ◽  
Population Based ◽  
Cancer Type ◽  
Breast Cancer Patients ◽  
Breast And Ovarian Cancer ◽  
Pathogenic Variants ◽  
Genetic Test Results

PURPOSE Genetic testing for cancer risk has expanded rapidly. We examined clinical genetic testing and results among population-based patients with breast and ovarian cancer. METHODS The study included all women 20 years of age or older diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014 and reported to the SEER registries covering the entire state populations. SEER data were linked to results from four laboratories that performed nearly all germline cancer genetic testing. Testing use and results were analyzed at the gene level. RESULTS There were 77,085 patients with breast cancer and 6,001 with ovarian cancer. Nearly one quarter of those with breast cancer (24.1%) and one third of those with ovarian cancer (30.9%) had genetic test results. Among patients with ovarian cancer, testing was lower in blacks (21.6%; 95% CI, 18.1% to 25.4%; v whites, 33.8%; 95% CI, 32.3% to 35.3%) and uninsured patients (20.8%; 95% CI, 15.5% to 26.9%; v insured patients, 35.3%; 95% CI, 33.8% to 36.9%). Prevalent pathogenic variants in patients with breast cancer were BRCA1 (3.2%), BRCA2 (3.1%), CHEK 2 (1.6%), PALB2 (1.0%), ATM (0.7%), and NBN (0.4%); in patients with ovarian cancer, prevalent pathogenic variants were BRCA1 (8.7%), BRCA2 (5.8%), CHEK2 (1.4%), BRIP1 (0.9%), MSH2 (0.8%), and ATM (0.6%). Racial/ethnic differences in pathogenic variants included BRCA1 (ovarian cancer: whites, 7.2%; 95% CI, 5.9% to 8.8%; v Hispanics, 16.1%; 95% CI, 11.8% to 21.2%) and CHEK2 (breast cancer: whites, 2.3%; 95% CI, 1.8% to 2.8%; v blacks, 0.1%; 95% CI, 0% to 0.8%). When tested for all genes that current guidelines designate as associated with their cancer type, 7.8% of patients with breast cancer and 14.5% of patients with ovarian cancer had pathogenic variants. CONCLUSION Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement.

Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study

The Lancet ◽  
2002 ◽  
Vol 360 (9337) ◽  
pp. 891-894 ◽  
Author(s):  
Kjell Bergfeldt ◽  
Bosse Rydh ◽  
Fredrik Granath ◽  
Henrik Grönberg ◽  
Lukman Thalib ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cohort Study ◽  
Family History ◽  
Cancer Patients ◽  
Population Based ◽  
Breast Cancer Patients ◽  
History Of

Risk Factors for Ovarian Cancers With and Without Microsatellite Instability

2014 ◽  
Vol 24 (4) ◽  
pp. 664-669 ◽  
Author(s):  
Yakir Segev ◽  
Tuya Pal ◽  
Barry Rosen ◽  
John R. McLaughlin ◽  
Thomas A. Sellers ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ovarian Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Contraceptive Use ◽  
Population Based ◽  
Tubal Ligation ◽  
Oral Contraceptive Use ◽  
Ovarian Cancers ◽  
Histologic Subtypes

ObjectiveIn a population-based sample of epithelial ovarian cancers, the objective of this study was to evaluate the association between microsatellite instability (MSI) status and the following factors: (1) ovarian cancer risk factors and (2) the distribution of the specific histologic subtypes.Patients and MethodsParticipants were drawn from 3 population-based studies of primary epithelial ovarian cancer; tumor DNA was analyzed using 5 standardized microsatellite markers to assess the MSI status. Patients were divided into 3 groups (MSI-high, MSI-low, and MSI-stable) according to the National Cancer Institute criteria. We compared the prevalence of specific known risk and protective factors among the 3 subgroups, including body mass index, smoking history, parity, BRCA1 and BRCA2 mutation status, past oral contraceptive use, and tubal ligation. Similarly, we compared the distribution of the histologic subtypes among the 3 subgroups.ResultsA total of 917 ovarian cancer patients were included. One hundred twenty-seven cases of cancer (13.8%) were MSI-high. Subgroup analyses according to smoking, body mass index, parity, past oral contraceptive use, and past tubal ligation did not reveal any statistically significant differences among the groups. Among the 29 patients with BRCA1 mutations, 20.7% had MSI-high cancers compared with 5.9% among 17 patients with BRCA2 mutations. The proportions of different ovarian cancer histologies among the various MSI subgroups were similar.ConclusionsThe prevalence of risk and protective factors among ovarian cancer patients is similar for cancers with and without MSI. The distributions of MSI do not differ significantly among ovarian cancers with different histologies. Ovarian cancer patients with BRCA1 mutations had a 21% rate of MSI-high tumors compared with 6% among patients with BRCA2 mutations, but this difference was not statistically significant.

Sign in / Sign up

Export Citation Format

Share Document